The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients | Zendy

ShangGin Wu | Zendy; Yinan Liu | Zendy; MengFeng Tsai | Zendy; YihLeong Chang | Zendy; ChongJen Yu | Zendy; PanChyr Yang | Zendy; James ChihHsin Yang | Zendy; YuehFeng Wen | Zendy; JinYuan Shih | Zendy

Open Access

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Author(s) -

ShangGin Wu,

Yinan Liu,

MengFeng Tsai,

YihLeong Chang,

ChongJen Yu,

PanChyr Yang,

James ChihHsin Yang,

YuehFeng Wen,

JinYuan Shih

Publication year - 2016

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.7189

Subject(s) - afatinib , t790m , medicine , kras , gefitinib , lung cancer , epidermal growth factor receptor , osimertinib , cancer research , lapatinib , neuroblastoma ras viral oncogene homolog , cancer , resistance mutation , oncology , tyrosine kinase inhibitor , erlotinib , biology , colorectal cancer , trastuzumab , breast cancer , gene , reverse transcriptase , rna , biochemistry

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are associated with favorable response in EGFR mutant lung cancer. Acquired resistance to reversible EGFR TKIs remains a significant barrier, and acquired EGFR T790M-mutation is the major mechanism. Second-generation irreversible EGFR TKI, afatinib, had also been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research